Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

Fig. 4

Month wise ≥ 2 g/dl Hb reduction with reference of ITPA rs11273547 CC and CA genotype. Months are presented as M1, M2, M3, M4, M5, M6. The bars present percentage of patients with each ITPA genotype experience hemoglobin reduction. Significantly high number of patients with ITPA SNP rs1127354-CC experience ≥ 2 g/dl Hb reduction at months M1, M2, and M4 mentioned by P value

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us